Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
Status:
Enrolling by invitation
Trial end date:
2024-07-07
Target enrollment:
Participant gender:
Summary
An open-label, multicenter, phase I dose-escalation study to assess the safety,
Pharmacokinetic (PK), immunogenicity and preliminary anti-tumor activity of ZV0203 in
patients with HER2-Positive advanced solid tumors